The automated production procedure is currently used in the ongoing phase II/III study, aiming to validate the use of [68Ga]Ga-ABY-025/PET-CT for non-invasive assessment of HER2-status in breast cancers in a multicenter setting (ClinicalTrials.gov: NCT03655353). This evidence concerns the gene ERBB2 and breast carcinoma.